Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $0.84, $0.27 better than the analyst estimate of $0.57. Revenue for the quarter came in at $46 million versus the consensus estimate of $51.1 million.

2020 Expense Guidance

• R&D spend in 2020, on a non-GAAP basis, is expected to be $46-$50 million, as compared to $31 million in 2019.
• SG&A spend in 2020, on a non-GAAP basis, is expected to be $61-$64 million, as compared to $56 million in 2019.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.